Skip to main content
. Author manuscript; available in PMC: 2019 Sep 16.
Published in final edited form as: Curr Pharm Des. 2017 Nov 16;23(29):4226–4246. doi: 10.2174/1381612823666170616082125

Table 5.

Small molecular inhibitors targeting STAT3

Inhibitor Target Types of cancer/transformed cell lines
PY*LKTK [165] SH2 domain Transformed fibroblasts
STA-21 [166] SH2 domain Breast cancer
LLL-3 [167] SH2 domain Breast cancer
Stattic [168] SH2 domain Breast cancer
S3I-201 [169] SH2 domain Breast cancer, hepatocellular carcinoma
S3I-M2001 [170] SH2 domain Breast cancer, pancreatic cancer
BP-1–102 [171] SH2 domain Breast cancer, lung cancer
HIC 1 [172] DNA binding domain Breast cancer
IS3–295 [173] DNA binding domain Colon cancer
DBD-1 [174] DNA binding domain Melanoma
InS3–54 [175] DNA binding domain Breast cancer, lung cancer
ST3-H2A2 [178] N-terminal domain Prostate cancer
G-quartet ODN [184, 185] SH2 domain Head and neck cancer, breast cancer, prostate cancer